The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
VORANIGO (Servier Laboratories (Aust) Pty Ltd)
Product name
VORANIGO
Date registered
Evaluation commenced
Decision date
Approval time
133 (255 working days)
Active ingredients
vorasidenib
Registration type
NCE/NBE
Indication
VORANIGO is indicated for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and paediatric patients 12 years and older, who are not in need of immediate chemotherapy or radiotherapy following surgical intervention.